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Background & aims: Patients with intestinal failure (IF) are dependent on long-term home parenteral
nutrition (HPN) to ensure growth and development. The primary aim of the present study was to assess
bone mineral density (BMD) and vitamin D status in paediatric IF patients on HPN and a group of healthy
children aged 2e18 years. Secondary aims were to assess growth, body composition, nutrient provision
and physical activity.
Methods: An observational cross-sectional study was performed at Oslo University Hospital and at the
Department of Nutrition, University of Oslo, from January to September 2017. Dual energy x-ray ab-
sorptiometry (DXA; Lunar Prodigy in IF patients and Lunar iDXA in healthy subjects) was performed to
assess BMD and body composition. BMD z-score (BMDz) was calculated for total body and lumbar spine
L2-L4 based on the integrated reference population in the software. Weight and height were measured
for growth assessment. Nutrient provision was assessed by a 4-day food record. Blood samples were
analysed for 25-hydroxy-vitamin D (25(OH)D) and 1,25-dihydroxyvitamin D (1,25(OH)2D). Physical ac-
tivity was reported by a questionnaire.
Results: Nineteen IF patients and 50 healthy children were included. The mean age of participants was
10.0 years. The aetiology of IF patients was paediatric intestinal pseudo-obstruction (58%), short bowel
syndrome (26%), and intestinal enteropathy (16%). Lower median BMDz for total body (0.4 vs 1.1,
P < 0.001) and lumbar spine L2-L4 (0.9 vs 0.2, P ¼ 0.01) were found in the IF group compared with the
healthy children. Vitamin D provision was significantly higher in IF patients (17 mg/d vs 5.3 mg/d,
P < 0.001). Both groups were sufficient in 25(OH)D (IF patients 71 nmol/L vs healthy 81 nmol/L).
Nevertheless, IF patients had significantly lower 1,25(OH)2D than healthy children (71 pmol/L vs
138 pmol/L, P < 0.001). The IF group was significantly shorter (height for age z-score 1,5 vs 0,1,
P ¼ 0.001) and lighter (weight for age z-score 1,0 vs 0,1, P ¼ 0.009) compared with the healthy subjects.
BMIz did not differ; however, body fat percentage was significantly higher in IF patients compared withz, Bone mineral density z-
x for age z-score; ESPGHAN,
patology and Nutrition; Htz,
n; IF, Intestinal failure; NNR,
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J.A. Kvammen et al. / Clinical Nutrition ESPEN 39 (2020) 234e241 235healthy children (34% vs 25%, P ¼ 0.02). A lower frequency of physical activity was found in the IF group
compared with the healthy group (P ¼ 0.001).
Conclusions: Paediatric IF patients on HPN had lower BMD, impaired growth, and higher body fat per-
centage in comparison with the healthy children. Despite a higher total supply of vitamin D in the IF
group, the levels of 25(OH)D did not differ. Nevertheless, a significantly lower level of 1,25(OH)2D was
found in IF patients. The results raise questions regarding differences between oral and parenteral
vitamin D provision and whether intestinal function is important for the metabolism of vitamin D.
Trial identification number: Clinical Trials AEV2017/1. 2016/391/REK sør-øst B
Revision number: CLNESP-D-20-00022.
© 2020 The Author(s). Published by Elsevier Ltd on behalf of European Society for Clinical Nutrition and
Metabolism. This is an open access article under the CC BY license (http://creativecommons.org/licenses/
by/4.0/).1. Introduction
Intestinal failure (IF) is a consequence of a reduced mass or
function of the gut. Long-term home parenteral nutrition (HPN) is
required to supply enough fluid, energy, macronutrients, and
micronutrients. The most common diagnosis related to IF is short
bowel syndrome, congenital absorptive defects, and motility dis-
orders [1]. The reported prevalence varies across studies, ranging
from 9.6 children per million in the Netherlands to 13.7 per million
in the United Kingdom [2,3].
Metabolic bone disease in associationwith long-term parenteral
nutrition (PN) was first described in paediatric patients in 2010 [4].
Peak bone mass refer to the maximum amount of bone accrued in
an individual during young adulthood. It can be defined as the
amount of bony tissue present at the end of the skeletal maturation
[5] and occurs by the end of the second or early in the third decade
of life [6]. Lifestyle factors influence 20e40% of adult peak bone
mass. Therefore, optimization of modifiable lifestyle factors in
childhood and adolescence is important for the prevention of
osteoporosis, fractures, and bone pain. Evidence has been found for
a positive contribution from calcium, vitamin D, and physical ac-
tivity on bone health [7]. Due to the risk of precipitations in
parenteral nutrition solutions, ensuring adequate amounts of cal-
cium and phosphorus may be difficult. Poor nutritional status,
including vitamin D deficiency, growth failure, and high fat mass,
have been found in IF patients [4,8e13]. This can be related to
suboptimal PN, malabsorption, and faecal loss of energy, proteins,
fluids, and electrolytes. Inflammation, medical treatments (e.g.
steroids), inactivity, and genetic factors may also contribute to poor
bone health [7,14].
Few studies have analysed bone mineral density (BMD) and
vitamin D status in children with IF on HPN. In particular, studies
including data on nutrient supply from both parenteral and enteral
nutrition routes are lacking. The primary aim of this study was to
assess BMD and vitamin D status in a group of paediatric IF patients
on HPN in comparison with a group of healthy children. The sec-
ondary aims were to assess growth, body composition, nutrient
provision, and physical activity between the two groups.2. Materials and methods
2.1. Subjects
An observational cross-sectional study was conducted on pae-
diatric patients with IF treated with long-term HPN and a group of
healthy children from March to September 2017. Inclusion criteria
were patients aged 2e18 years and dependent on HPN for more
than 6 months at routine follow-up examination at the Paediatric
Intestinal Failure Team at Oslo University Hospital (OUH). A refer-
ence group of healthy children in the same age group was recruitedusing advertisement via social media. The inclusion criteria were
residence in the Oslo area and eating a diet without any re-
strictions. Clinical and demographic data were obtained from
medical records and questionnaires. Patients were examined at the
hospital and the healthy participants at the Clinical Nutrition
Research Centre at the University of Oslo (UiO). A subgroup of age-
and sex-matched healthy participants was used to explore the
vitamin D results.
2.2. Anthropometry
Patients’ weight (kg) was measured by Seca weight (model
7701321004, seca gmbh & co. kg, Germany) and height (cm) by a
stadiometer (Holtain Limited, Britain). Healthy participants were
measured using a combined digital measuring station (Seca 284,
seca gmbh & co. kg, Germany). Z-scores for weight for age (Wtz),
height for age (Htz), and BMI for age (BMIz) were calculated based
on the Norwegian reference population [15]. Underweight was
defined BMIz <e2 and overweight as BMIz >2. Stunting was
defined as Htz <e2.
2.3. Dual-energy x-ray absorptiometry
Dual-energy x-ray absorptiometry (DXA) is the preferred
method for assessing bone and body composition as it is rapid and
precise with robust paediatric reference data. DXA is considered
safe with low effective x-ray dose (range, 0.03e15.2 mSV) [16].
Children aged 5 years and older were measured for BMD (g/cm2)
and bone mineral content (BMC, g) total body and anterior-
posterior lumbar spine L2-L4, fat percentage, and lean mass. BMD
z-score (BMDz) were calculated according to available reference
materials in the software [17]. IF patients underwent DXA using
Lunar Prodigy, software enCORE, version 16 (GE Healthcare, Lunar
Corp., Madison,WI, USA) at the Department of Endocrinology, OUH.
Healthy participants weremeasured at UiO by Lunar iDXA, software
enCORE, version 16 (GE Healthcare). The scanners were calibrated
daily by a phantom, and the same person evaluated all data. DXA is
an area measurement and does not capture the depth of bone.
Hence, volumetric BMD for children with poor growth will be
underestimated. Adjusting for this is recommended [18], and re-
sults were adjusted for skeletal age measured by hand radiograph
in three IF patients with Htz <e2. Suboptimal BMDz was defined as
e1 to 1.99, and low BMDz defined as e2 [18].
2.4. Nutrient provision
All participants completed a 4-day food record [19], using
household measures and a booklet of portion sizes [20]. All foods,
drinks, and dietary supplements were recorded. IF patients were
also instructed how to record tube-feeding and PN. Enteral
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port. DietistPro, a software for dietary analysis based on the Nor-
wegian Food Composition Table [21], was used by trained dietitians
to calculate nutrient intake. PN prescriptions were provided by the
Hospital Pharmacies, and mean supply during 7 days was calcu-
lated and used in the analysis of total nutrient provision. Enteral
nutrition was compared with recommended intake (RI) from the
Nordic Nutrition Recommendations [22]. PN was compared with
European Society of Paediatric Gastroenterology, Hepatology and
Nutrition (ESPGHAN)/European Society for Clinical Nutrition and
Metabolism/European Society of Paediatric Research/Colorado So-
ciety for Parenteral and Enteral Nutrition recommendations
[23e28]. Estimated energy requirement was calculated using sex,
age, and weight and compared with Nordic Nutrition Recommen-
dations for low activity level [22]. Parents and medical records
provided data on the initiation and duration of PN.2.5. Blood analyses
Blood samples were performed according to routine procedures
at the study visit. The analyses were done at the Hormone Labo-
ratory, OUH. Vitamin 25(OH)D was quantified by liquid
chromatographyetandem mass spectrometry with determination
of 25-hydroxyvitamin D2 (25(OH)D2) and 25-hydroxyvitamin D3
(25(OH)D3) levels. The sum of 25(OH)D2 and 25(OH)D3 levels is
referred to as 25(OH)D. The coefficients of variation were 10e17%
[29]. The method was standardised according to the Vitamin D
Standardization Program. Vitamin D sufficiency was defined as
total 25(OH)D > 50 nmol/L [30e32].
Enzyme immunoassay (IDS Nordic) was used to measure
1,25(OH)2D. The reference range for 1,25(OH)2D was 75e250 pmol/
L for children aged 3e18 years according to the manufacturer. The
coefficients of variation were 9e11% [29].
Plasma parathyroid hormone (PTH), alkaline phosphatase (ALP),
ionised calcium, phosphate, creatinine, urea, albumin, bilirubin,
aspartate aminotransferase (ASAT), alanine aminotransferase
(ALAT), gamma glutamyltransferase (GT) and C-reactive protein
were analysed at the Department of Medical Biochemistry, OUH.2.6. Physical activity
To assess usual physical activity level, the participants filled out
a questionnaire on frequency per week of sessions lasting more
than 30 min (“never or less than once,” “1e3 sessions,” “4 sessions
or more”). Participation in different sports and the intensity of
physical activity were also asked for in the questionnaire.Table 1
Characteristics of participants.
Intestinal failure Healthy P-value
(n ¼ 19) (n ¼ 50)
Age, years (mean, SD) 10.1 (3.5) 10.0 (3.6) 0.93a
Gender (boys, n (%)) 13 (68) 18 (36) 0.03b
Diagnosis, n (%)
Motility disorder 11 (58)
Short bowel syndrome 5 (26)
Intestinal enteropathy 3 (16)
Anthropometry, mean (SD)
Height, cm 130.3 (19.2) 139.9 (18.4) 0.07a
Weight, kg 31.1 (11.2) 36.7 (14.4) 0.13a
BMI, kg/m2 17.9 (2.4) 17.9 (3.2) 0.98a
SD: standard deviation.
a Independent-samples t-test.
b Chi-square, Continuity Correction.2.7. Statistical considerations
Statistical analyses were performed using IBM SPSS Statistics for
Windows, version 25 (Armonk, New York). ShapiroeWilk test was
used for normality testing. Normally distributed data were pre-
sented as means and standard deviations, and an independent-
samples t-test was used for analysis between pairs of groups. Non
normally distributed data were presented as medians with 25th to
75th percentiles, and analysis between pairs of groups was per-
formed by ManneWhitney U test. Categorical data were presented
as frequencies, and Chi-square or Fisher's exact test were used to
test differences between groups. Missing variables were excluded
pairwise. The level of significancewas two-sided and set to P< 0.05.
Subgroup analyses for vitamin D status were performed using age-
and sex-matched healthy participants in comparison with the IF
patients.2.8. Ethical statement
Informed consent was collected from parents and participants
aged 16e18 years. Approval for the study was obtained from the
Regional Committee for Medical and Health Research Ethics in
Norway (REC nr. 2016/391) and the Head of the Department and
the Research committee, OUH. The study was registered in Clinical
Trials (AEV2017/1), and the ethical standards of the Declaration of
Helsinki were followed.
3. Results
3.1. Characteristics of participants
The study included all 19 available IF patients at OUH and a
group of 50 healthy children. Characteristics of the participants are
presented in Table 1. There were no differences in age between the
groups (mean, 10.1 and 10.0 years, respectively). Pubertal stage was
not assessed, but 32% of patients in the IF group and 30% of the
healthy children were older than 12 years. There were significantly
more boys in the IF group. The aetiology of IF patients was paedi-
atric intestinal pseudo-obstruction (58%), short bowel syndrome
(26%), and intestinal enteropathy (16%). Most subjects were
Caucasian; one IF patient and one healthy child were Asian, and one
patient was African. The IF patients had been on HPN for a median
of 4.4 years at inclusion.
The IF group was significantly shorter (Htz) and lighter (Wtz)
compared with the healthy group. BMIz did not differ between
groups; however, body fat percentage was significantly higher in
the IF group (Table 2). Overweight (BMIz >2) was found in 11% of IF
patients and none of the healthy patients (P ¼ 0.07), whereas none
of the IF patients and 4% of the healthy children were underweight
(BMIz <e2). Among the IF patients, 33% were classified as stunted
compared with 4% of the healthy participants (P ¼ 0.003).
3.2. Bone mineral density
Twelve of the IF patients and 46 of the healthy children were
measured by DXA. Five IF patients and one healthy child could not
manage the procedure, and two IF patients and three healthy pa-
tients were younger than 5 years. Two healthy children did not
measure lumbar spine. In three of the DXA-measured IF patients,
BMDz were adjusted for delayed growth according to skeletal age.
Significantly lower median BMDz for total body (0.4 vs 1.1,
P < 0.001) and lumbar spine L2-L4 (0.9 vs 0.2, P ¼ 0.01) were
found in the IF group compared with the healthy group (Fig. 1). A
suboptimal BMDz for total body was found in 25% of the IF patients.
Table 2
Growth, body fat percentage, and blood results in intestinal failure patients and in
healthy children.
Intestinal failure Healthy P-value
(n ¼ 19) (n ¼ 50)
Growth, mean (SD)
Htz 1.5 (1.7) 0.1 (1.2) 0.001b
Wtz 1.0 (1.6) 0.1 (0.9) 0.009b
BMIz 0.2 (1.0) 0.0 (1.1) 0.51b
Body composition, median (25e75 percentile)a
Body-fat, % 33.6 (24.6e38.9) 24.9 (20.9e27.9) 0.02c
Plasma, median (25e75 percentile)
PTH, pmol/L 4.6 (3.0e5.0) 4.1 (3.3e5.3) 0.97c
ALP, U/L 218 (200e301) 220 (174e257) 0.25c
Ionized calcium, mmol/L 1.27 (1.23e1.30) 1.26 (1.23e1.28) 0.68c
Phosphate, mmol/L 1.58 (1.30e1.60) 1.40 (1.30e1.50) 0.35c
Creatinine, mmol/L 37 (31e44)
C-reactive protein 0.5 (0.5e46.5) 0.5 (0.5e34) 0.35c
SD: standard deviation, Htz: Height for age z-score, Wtz: Weight for age z-score,
BMIz: Body mass index for age z-score, PTH: parathyroid hormone; ALP: alkaline
phosphatase.
a n ¼ 12/46, dual energy x-ray absorptiometry.
b Independent-samples t-test.
c ManneWhitney U test.
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patients, and suboptimal in 5% of healthy participants.3.3. Nutrient provision
Parenteral, enteral, and total dietary provisions of macronutri-
ents, vitamin D, calcium, and phosphorus are presented in Table 3.
PN was used by all and enteral nutrition (oral diet and/or enteral
nutrition support) by 79% of IF patients. Four patients were on total
parenteral nutrition (TPN). Total energy intake was median 105% of
RI in IF patients and 85% of RI in healthy children (P ¼ 0.08). IF
patients received a median of 76% of their estimated energy
requirement from PN. Total energy, protein, and fat provision per
kilogram (kg) were not significantly different, but carbohydrates
were higher in IF patients comparedwith healthy children (9.3 g/kg
vs 5.9 g/kg, P ¼ 0.005; Table 3). The carbohydrate provision was
higher than recommended by the parenteral guideline [26]. Amino
acids [25] and lipids [27] were within recommendations.
Total vitamin D provision was significantly higher in IF patients
compared with healthy children (17 mg/d vs 5.3 mg/d, P < 0.001;
Table 3). Parenteral vitamin D2 (median 10 mg/d) was used by 95%,
and 1 patient was on fat-free PN. Oral vitamin D supplements were
used by 32% of IF patients and 28% of healthy children.Fig. 1. BMD z-scores in paediatric intestinal failure patients (n ¼ 12) and healthy children (to
(P ¼ 0.01; Mann Whitney U test). Results were adjusted for delayed height (Htz <e2) in thAll IF patients had parenteral calcium (CaCl2) supply below
recommendation. For parenteral phosphorus, 47% had an intake
below the recommendation [28]. Sodium glycerophosphate
(C3H7Na2O6P) was used by all IF patients, except one patient using
monopotassium phosphate (KH2PO4). One IF patient used an oral
calcium supplement (1000 mg/day). Enteral calcium intake was
less than RI in 84% of IF patients and in 42% of healthy children [22].
Enteral phosphorus was less than RI in 74% of IF patients, but none
of the healthy subjects. Enteral calcium and phosphorus intake
were significantly lower in IF patients compared with healthy
children (Table 3).3.4. Vitamin D status
Both groups were sufficient in 25-hydroxy-vitamin D (25(OH)D)
(IF patients 71 nmol/L vs healthy 81 nmol/L, P ¼ 0.29; Fig. 2a).
Analyses for age- and sex-matched groups did not change results
(IF patients 71 nmol/L vs healthy 81 nmol/L, P ¼ 0.36). No signifi-
cant difference in 25(OH)D was found for healthy participants
included during MarcheJune (n ¼ 34) compared with
AugusteSeptember (80 nmol/L vs 86 nmol/L, P ¼ 0.24), or for
matched groups (85 nmol/L vs 81 nmol/L, P ¼ 0.81). Seasonal an-
alyses of IF patients could not be done as all were included during
MarcheJune. Vitamin 25(OH)D < 50 nmol/L was found in two IF
patients (10%), and one of these had severe deficiency (14 nmol/L).
One healthy participant had 25(OH)D at 45 nmol/L. Vitamin 25(OH)
D  75 nmol/L was found in 47% of the IF group and 66% of the
healthy children.
The IF group had significantly lower 1,25-dihydroxyvitamin D
levels compared with the healthy group (71 pmol/L vs 138 pmol/L,
P < 0.001; Fig. 2b). Subgroup analyses for age- and sex-matched
groups were performed, and a significant difference between the
IF group and healthy children was still present (71 pmol/L vs
140 pmol/L, P ¼ 0.001).3.5. Other blood biomarkers
No significant differences were found between the IF patients
and the healthy group for blood levels of PTH, ALP, ionized calcium,
or phosphate (Table 2). Creatinine and urea were normal in all
except two IF patients with elevated levels. Apart from elevated
levels of; ASAT in three, ALAT in five and GT in two, all IF patients
had normal liver function tests, including normal values for bili-
rubin and albumin. One IF patient had elevated ASAT, ALAT and GT,
and was the only participant detected with severe vitamin D defi-
ciency; 25 (OH)D 14 nmol/L.tal body n ¼ 46, L2-L4 n ¼ 44) in (a) total body (P < 0.001) and (b) lumbar spine L2-L4
ree intestinal failure patients.
Table 3
Daily nutrient provision in paediatric intestinal failure patients and healthy children and guidelines for enteral and parenteral nutrition.
Median (25e75 percentile) Intestinal failure Healthy P-valuea Guideline Guideline
(n ¼ 19) (n ¼ 50) enteralb parenteralc
Parenteral nutrition
Energy, kcal 1414 (687e1804)
Energy, kcal/kg 37 (32e53) 75e25
Amino acids, g 45.4 (21.7e58)
Amino acids, g/kg 1.3 (1.1e1.8) 2.5e1.0
Glucose, g 210.4 (95.5e265.3)
Glucose, g/kg 5.5 (4.4e8.1) 8.6e1.4
Lipids, g 32.7 (17.0e55.0)
Lipids, g/kg 1.1 (0.9e1.5) 3
Vitamin D, mg 10.0 (7.5e15.0) 10e15
Calcium, mmol/kg 0.15 (0.13e0.18) 0.25e0.4
Phosphorus, mmol/kg 0.20 (0.16e0.23) 0.2e0.7
Enteral nutrition
Energy, kcal 705 (73e1100) 1913 (1499e2052) <0.001
Energy, kcal/kg 24 (2e35) 51 (39e69) <0.001
Protein, g 22.8 (2.0e38.3) 72.5 (57.3e90.5) <0.001
Protein, g/kg 1.0 (0.1e1.3) 2.3 (1.8e2.7) <0.001 0.9
Carbohydrates, g 94.6 (15.6e138.9) 216.1 (174.7e249.8) <0.001
Carbohydrates, g/kg 3.0 (0.3e4.7) 5.9 (4.4e8.3) <0.001
Lipids, g 20.8 (0.0e43.8) 67.0 (53.9e78.5) <0.001
Lipids, g/kg 0.7 (0.0e1.5) 2.0 (1.5e2.5) <0.001
Vitamin D, mg 3.0 (0.9e10.1) 5.3 (2.7e9.9) 0.42 10
Calcium, mg 187 (20e574) 801 (652e985) <0.001 600e900
Phosphate, mg 368 (21e658) 1349 (1061e1746) <0.001 470e700
Total nutrient provision
Energy, kcal 1834 (1278e2399) 1913 (1499e2052) 0.74
Energy, kcal/kg 67 (42e74) 51 (39e69) 0.12 75e25
Protein, g 63.0 (48.3e77.0) 72.5 (57.3e90.5) 0.05
Protein, g/kg 2.2 (1.4e2.6) 2.3 (1.8e2.7) 0.48 0.9 2.5e1.0
Carbohydrates, g 281.6 (181.9e368.0) 216.1 (174.7e249.8) 0.03
Carbohydrates, g/kg 9.3 (6.2e11.2) 5.9 (4.4e8.3) 0.005 8.6e1.4
Lipids, g 55.0 (37.1e73.6) 67.0 (53.9e78.5) 0.13
Lipids, g/kg 2.0 (1.4e2.3) 2.0 (1.5e2.5) 0.79 3
Vitamin D, mg 17.0 (10.5e26.2) 5.3 (2.7e9.9) <0.001 10 10e15
PN: parenteral nutrition, EN: oral diet and/or enteral nutrition support.
a ManneWhitney U test.
b Enteral recommendations for low activity level (The Nordic Nutrition Recommendations) [21].
c Parenteral recommendations for stable/recovery phase in children 1e18 years or weight >11 kg (European Society of Paediatric Gastroenterology, Hepatology and
Nutrition (ESPGHAN)/European Society for Clinical Nutrition and Metabolism/European Society of Paediatric Research/Colorado Society for Parenteral and Enteral Nutrition
recommendations) [22e27].
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An overall lower level of physical activity participation was
found in IF patients compared with healthy subjects (Table 4). A
significant difference in sports participationwas detected (26 vs 2%,
P ¼ 0.01), and the intensity of physical activity participation was
lower in IF patients than in healthy participants (P < 0.001; data not
shown).Fig. 2. Vitamin D status in paediatric intestinal failure patients (n ¼ 19) and healthy childre
vitamin D (P < 0.001; Mann Whitney U test).4. Discussion
This cross-sectional study of paediatric IF patients on long-term
HPN revealed lower BMD, impaired growth, and higher body fat
percentage in comparison with healthy children. Vitamin D provi-
sion was higher in the IF patients compared with the healthy
children, and total intake was in line with recommendations. The
level of 25(OH)D was sufficient, and not different between the twon (n ¼ 48) measured by (a) 25-hydroxy-vitamin D (P ¼ 0.29) and (b) 1,25-dihydroxy-
Table 4
Sessions of physical activity per week in the intestinal failure patients and in the
healthy children.
Intestinal failure Healthy P-valuea
n (%) n (%)
Sessions per week
<1 5 (26.3) 1 (2) 0.001
1e3 12 (63.2) 28 (56)
4 2 (10.5) 21 (42)
a Fisher's exact test, effect size by Cramer's V ¼ 0.444, P ¼ 0.001.
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found in IF patients.
Significantly lower BMDz for total body and lumbar spine L2-L4
were found in IF patients compared with healthy children (Fig. 1).
Total body BMDz was suboptimal in 25% of IF patients. In L2-L4 25%
of IF patients had low, and 17% had suboptimal BMDz. Other studies
support this finding [4,9,12,13,33e36], with prevalence values from
12.5 to 88%. Differences between studies are related to selected cut-
off points, small study populations, heterogeneous aetiology,
different skeletal sites reported, and differences in the correction
methods for growth delay. In addition, most studies reported re-
sults for a combination of patients who were receiving and weaned
off PN.
Stunting was found in 1/3 of IF patients, a significantly higher
proportion than in healthy children. Other studies have confirmed
the risk of growth delay in this patient group [4,8e12,34e37].
Growth delay can be multifactorial, e.g. related to the disease itself,
genetics, inflammation, medications used, and/or related to
malnutrition. In this study, a low provision of calcium and phos-
phate was found simultaneously to a low serum 1,25(OH)2D. This
combination increase the risk of growth delay and bone mineral
deficits [7,38].
Lower physical activity was found in IF patients in comparison
with healthy children (Table 4). This may be an important factor
contributing to the reduced BMDz (Fig. 1) and higher body fat
percentage detected in the IF patients (Table 2). Reliance on PN
might reduce the possibility of participating in physical activities.
Lean mass is a strong predictor for bone mass, as muscle force
stimulates bone mineral accrual in children and adolescence [7].
Therefore, it is important to include individual advice on physical
activity as part of the follow-up routine of patients on HPN.
High glucose supply could contribute to an increase in fat mass
in IF patients. The proportion of overweight was not different be-
tween the two groups, but carbohydrate provision was higher in IF
patients.. Compared with parenteral guidelines, total carbohydrate
provision was above the recommendation [26]. This recommen-
dationmay also be discussed in terms of the importance of meeting
energy requirements to ensure growth, and the alternatives of
increasing lipids and/or amino acids. The recommendation for
carbohydrates states that both enteral and parenteral supply
should be evaluated together [26]. This is different from the rec-
ommendations for parenteral amino acids [25] and lipids [27]
where enteral supply is not mentioned.
Differences in vitamin D, calcium, and phosphate provisionwere
present between the groups (Table 3). Parenteral vitamin D supply
(10 mg/d) was in accordance with the guideline of 10e15 mg/day
[23]. The total vitamin D provision of IF patients was significantly
higher than in the healthy children (17 vs 5.3 mg/day). Enteral intake
was not different (3.0 vs 5.2 mg/day), both lower than RI of 10 mg/
day [22]. Total provision of available calcium and phosphate in the
IF group compared to the healthy is difficult to assess because of a
combined supply from enteral and parenteral routes, and that ab-
sorption may be affected in the IF patients. However, resultsindicates low supply of both minerals, which is negative for opti-
mization of bone health [7]. The combination with low vitamin
1,25(OH)2D may be even more negative as the active form plays an
important role in the control of calcium absorption in the intestine,
hence; in securing sufficient calcium available for bone minerali-
zation [7,38].
Vitamin 25(OH)D is regarded to be the best biomarker for
vitamin D status [30e32]. This study found sufficient levels of
25(OH)D in both groups. Vitamin 25(OH)D status was close to
optimal (Fig. 2a) [30e32]. Sun exposure might be higher in the
healthy group, and could explain adequate status even if dietary
provision was lower than in IF patients, and lower than recom-
mended for healthy children. Seasonal differences in vitamin D
status could be expected due to participants living in southern
Norway at latitude 58e61N [39,40]. However, no difference was
found for healthy participants included during MarcheJune
compared to AugusteSeptember. Other studies have reported
vitamin D insufficiency in 20e68% of paediatric IF patients
[12,13,33,34,36,37,41,42], which is more than the 5% found by
Appleman et al. [43], and the 10% found in the present study. An
explanation could be that these studies also included patients
weaned off PN, and hence their absorption could be compromised.
The close follow-up by the IF team may contribute to adequate
status in our study group.
Both D2 (vegetable/supplements) and D3 (skin/animal/supple-
ments) are transported to the liver and hydroxylated to 25(OH)D.
With sufficient and no difference in 25(OH)D between the groups,
the detection of a lower 1,25(OH)2D in the IF patients compared
with the healthy group is interesting (Fig. 2). This is different from
another study of paediatric IF patients on PN where a normal value
of 1,25(OH)2D was found [43]. Lower 1,25(OH)2D level raises
questions regarding the mechanism. Hypotheses may be a loss of
1,25(OH)2D, an inadequate activation of 25(OH)D, or increased
degradation of 1,25(OH)2D in the IF group. Low 1,25(OH)2D has
usually been explained by chronic renal failure, but creatinine
levels were normal in all except two IF patients (Table 2). PTH was
not different between the two groups (Table 2). Another possibility
could be that parenteral provision itself affects 1,25(OH)2D. All IF
patients received cyclical supply, median 12 h/day, and there is
little knowledge on how this affects metabolic biorhythms. Low
levels of 1,25(OH)2D have also been found in for example, pneu-
monia [44] and after bone marrow transplantation [45]. Disease
related factors, e.g. inflammation, could impact hydroxylation. A
hypothesis may be that IF patients have an increased level of
fibroblast growth factor 23 (FGF23). FGF23 down-regulate cyto-
chrome p450 27B1 (CYP27B1) expression, resulting in reduced
synthesis of 1,25(OH)2D. It is known that the activation from
25(OH)D to 1,25(OH)2D is dependent on hydroxylation by this
specific enzyme. CYP27B1 has been detected in different cells and
tissues, including the intestine [46]. Results may suggest that the
intestine is more important for the metabolism of vitamin D than
earlier recognized, and raises questions regarding differences in the
effect of oral and parenteral provision of vitamin D for the meta-
bolism into 1,25(OH)2D.
Strengths of this study are the inclusion of all available IF pa-
tients on HPN at our center, and the comparison with a group of
healthy children. An important strength was the detailed infor-
mation on total diet, including both enteral and parenteral provi-
sion. A cross-sectional design and small sample size are limitations,
and the results from this study must be interpreted with caution.
Another possible limitation is the gender difference between the
patients and the healthy children, even though the sub-analyses
indicated that this was of minor impact for the vitamin D results.
The healthy group was recruited by social advertisement, and could
therefore be healthier than the general population which is also a
J.A. Kvammen et al. / Clinical Nutrition ESPEN 39 (2020) 234e241240limitation. However, their dietary intake was comparable with re-
sults from the last national dietary investigation of 9-year-old
Norwegians [47]. DXA was not performed in 5 IF patients due to
issues of managing the examination. This might have contributed
to an underestimation of bone deficit, as most of these patients
were immobile. Pubertal stage, seasonal variations of vitamin D, or
calcium and phosphate in the urine, were not assessed, which also
are limitations of the study. The risk of type I errors due to multiple
analysis is crucial to be aware of, and is related to the explorative
study design.
Further studies are needed to confirm our results and improve
knowledge. Amulticenter RCTwith adequate power could compare
different modes of vitamin D, calcium and physical activity on bone
mass, body composition and vitamin D biomarkers. This design
could better answer questions regarding nutrition and lifestyle
interventions. We also suggest that future studies investigates
calciuria, phosphaturia, serum FGF23 and insulin resistance in IF
patients. Better understanding of advanced nutritional treatment
and its consequences on health is important as use of HPN is on the
increase due to better treatment and nutritional care of children
with IF.Conclusion
Paediatric IF patients on HPN had lower BMD, impaired growth,
and higher body fat percentage in comparison with healthy chil-
dren. Provision of glucose was high, calcium and phosphorus low
compared with recommendations for PN, and compared with
healthy children. Vitamin D provision was higher in IF patients
compared with the healthy children, and total intake as recom-
mended for PN. The levels of 25(OH)D were sufficient for both
groups. Nevertheless, a significantly lower 1,25(OH)2D level was
found in IF patients compared with healthy children. The results
raise questions regarding differences between oral and parenteral
vitamin D provision and whether intestinal function is important
for the metabolism of vitamin D.Statement of authorship
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